DUBLIN, Jan. 22, 2019 /PRNewswire/ --
The "Contract Biomanufacturing Services Global Market" report has been added to ResearchAndMarkets.com's offering.
The contract biomanufacturing global market is valued at $13.3 billion in 2018 and is expected to grow at a CAGR of 15.5% to reach $48.8 billion by 2027.
Biopharmaceutical companies are seeking operational efficiency, technical expertise in niche areas, regulatory support and the advantage of focusing on core competencies which are pushing them to outsource a part or whole of the research and manufacturing to smaller contract research organizations (CROs), contract development and manufacturing organizations (CDMOs) or Contract manufacturing organizations (CMOs).
Outsourcing has been viewed as a strategic imperative keeping in mind the complexities and capital that goes behind establishing a facility for biologic research and manufacture. Contract biomanufacturing is an increasing trend in the biologics outsourcing global market.
Due to the high demand for biologics and customized and integrated services that the contract manufacturing organizations (CMOs) provide, the manufacturing of biologic drugs in a contracted manner is being highly adopted. The outsourcing of manufacturing gives the opportunity to the large pharma companies to streamline their drug pipelines and also help bring the drugs to market faster.
The latest and cutting-edge technologies that have been installed by CMOs which include single-use bioreactors are creating huge potential for outsourcing market. Examples include, In April 2018 Wuxi Biologics planning to invest $381 million to open new biomanufacturing facility in Ireland, the new facility will use multiple single-use bioreactors for commercial biomanufacturing and it is designed to be able to run continuous bioprocessing.
The company intends to install a total of 48,000L fed-batch and 6,000L perfusion bioreactor.
Factors affecting the biologics contract manufacturing market include drivers such as globalization of outsourcing for biomanufacturing, increased funding from private investors and government for development of CMOs, the emergence of the latest technologies such as single-use bioreactors.
However, there are certain restraints that are hindering the growth of the market. These include high requirements for capital investments in setting up huge manufacturing facilities, the risk of product contamination and maintenance of production efficiency.
Entry of large pharmaceutical companies with excess capacity into contract manufacturing and stringent regulations such as mandatory GMP certifications is posing a huge threat to the market. Contrastingly, increasing biologics and biosimilar pipeline and successful collaborations between CMOs and biopharma companies are providing high growth opportunities for the contract biomanufacturing global market.
The market is dominated by top players like Lonza, Boehringer Ingelheim, Catalent, and Samsung Biologics. Other top
players in the contract biomanufacturing global market include Thermo Fisher (Patheon N.V.), Fujifilm Diosynth, JSR Corporation, Wuxi, AGC Asahi Glass (CMC Biologics), Rentschler Biotechnologies GmbH, CRL, Abbvie contract manufacturing, Merck KGaA.
Key Topics Covered:
1 Contract Biomanufacturing Global Market
1.1 Executive Summary
2 Market Analysis
2.1 Factors Influencing Market
2.1.1 Drivers And Opportunities
22.214.171.124 Globalization Of Outsourcing For Bio-Manufacturing
126.96.36.199 Increased Funding From Private Investors And Government For Development Of Cmos
188.8.131.52 The Emergence Of Single-Use Bioreactors
184.108.40.206 Increasing Biologics Approvals In The Past Year
220.127.116.11 Successful Collaboration And Low Cost For Outsourcing
2.1.2 Restraints And Threats
18.104.22.168 The High Requirement For Capital Investments Restraining Many Cmos To Enter The Biologics Space
22.214.171.124 Risk Of Product Contamination & Maintaining High Productivity
126.96.36.199 Entry Of Large Pharmaceutical Company With Excess Capacity Into The Cmo Market
188.8.131.52 Stringent Regulations And Mandatory Requirement Of Cgmp Certifications
3 Contract Biomanufacturing Services
3.2 Contract Biomanufacturing, By Process
3.2.1 Biomanufacturing By Mammalian Cell Culture
3.2.2 Biomanufacturing By Microbial Cell Culture
3.2.3 Biomanufacturing By Other Cell Culture
3.3 Contract Biomanufacturing Global Market, By End Users
3.3.1 Contract Biomanufacturing Of Diagnostics
3.3.2 Contract Biomanufacturing Of Research Reagents
3.3.3 Contract Biomanufacturing Of Therapeutics
3.4 Contract Biomanufacturing Global Market, By Region
3.5 Competitive Landscape
3.5.1 Capacity Comparison
3.5.2 Contract Biomanufacturing Global Market Share, By Leading Players
3.6 Company Developments
3.6.1 Merger And Acquisition By Cmos
3.6.3 Capacity Expansions
4 Company Profiles
4.1 Abzena Plc
4.2 Albany Molecular Research Inc
4.3 Asahi Glass Co. Ltd. (AGC Bioscience/CMC Biologics)
4.4 Boehringer Ingelheim
4.5 Catalent Inc.
4.6 Charles River Laboratories
4.7 Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation)
4.8 Horizon Discovery Group, Plc
4.9 JHL Biotech Inc.
4.10 Lonza Group
4.11 Merck KGaA
4.13 Rentschler Biotechnologie Gmbh
4.14 Samsung Biologics
4.15 JSR Life Sciences (Selexis SA)
4.16 Syngene International
4.17 Patheon N.V. (Thermo Fisher Scientific)
4.18 Wuxi Biologics (Wuxi Apptec)
- Abbvie Contract manufacturing
- Affinity Lifesciences
- Ajinomoto Althea, Inc.
- Alexion Pharmaceuticals
- AGC Asahi glass (CMC Biologics)
- Avid Bioservices
- Bharat Biotech Ltd
- Binex Co. Ltd.
- Bioconnect life sciences
- Bioreliance SAFC
- Boehringer Ingelheim
- Cadila Healthcare Ltd
- Catalent Inc.
- Cevec Pharmaceuticals GmbH
- Charles River Laboratories
- Cobra biologics
- Covance research products
- Cytovance Biologics
- Dendreon Corporation
- Europa Bioproducts
- Fujifilm Diosynth Biotechnologies
- GTP technology
- Horizon Discovery
- Inno biologics
- Innovent Bio
- Intas Pharmaceuticals
- JHL biotech
- JSR Corporation (KBI biopharma)
- Jubilant Hollister-Stier
- Kemwell Biopharma
- Lake Pharma
- Lampire Biological Laboratories
- Luina Bio
- Menarini Biotech s.r.l
- Merck GmbH
- Miltenyi Biotech GmbH
- Omnia biologics
- Paragon Bioservices
- Premas biotech Pvt Ltd
- Rentschler Biotechnologie
- Samsung Biologics
- Sandoz GmbH
- Scripps laboratories
- Selexis S.A.
- Serum Institute of India
- Therapure Biopharma
- Toyobo Co. Ltd.
- U-protein express BV
- Vifor Pharma Ltd
- Waisman clinical biomanufacturing
- Wuxi Apptec
- Zymeworks Inc.
For more information about this report visit https://www.researchandmarkets.com/research/nwd8bl/the_contract?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets